Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Cited In for PubMed (Select 2541915)

1.

Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.

Ingale J, Tran K, Kong L, Dey B, McKee K, Schief W, Kwong PD, Mascola JR, Wyatt RT.

J Virol. 2014 Dec;88(24):14002-16. doi: 10.1128/JVI.02614-14. Epub 2014 Sep 24.

2.

The productive entry pathway of HIV-1 in macrophages is dependent on endocytosis through lipid rafts containing CD4.

van Wilgenburg B, Moore MD, James WS, Cowley SA.

PLoS One. 2014 Jan 22;9(1):e86071. doi: 10.1371/journal.pone.0086071. eCollection 2014.

3.

Peptides presenting the binding site of human CD4 for the HIV-1 envelope glycoprotein gp120.

Meier J, Kassler K, Sticht H, Eichler J.

Beilstein J Org Chem. 2012;8:1858-66. doi: 10.3762/bjoc.8.214. Epub 2012 Oct 31.

4.
5.

Structural Basis for Species Selectivity in the HIV-1 gp120-CD4 Interaction: Restoring Affinity to gp120 in Murine CD4 Mimetic Peptides.

Kassler K, Meier J, Eichler J, Sticht H.

Adv Bioinformatics. 2011;2011:736593. doi: 10.1155/2011/736593. Epub 2012 Jan 19.

6.

Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences.

Misasi J, Chandran K, Yang JY, Considine B, Filone CM, Côté M, Sullivan N, Fabozzi G, Hensley L, Cunningham J.

J Virol. 2012 Mar;86(6):3284-92. doi: 10.1128/JVI.06346-11. Epub 2012 Jan 11.

7.

Inhibition of HIV-1 infection in ex vivo cervical tissue model of human vagina by palmitic acid; implications for a microbicide development.

Lin X, Paskaleva EE, Chang W, Shekhtman A, Canki M.

PLoS One. 2011;6(9):e24803. doi: 10.1371/journal.pone.0024803. Epub 2011 Sep 19.

8.

Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras.

Wheeler LA, Trifonova R, Vrbanac V, Basar E, McKernan S, Xu Z, Seung E, Deruaz M, Dudek T, Einarsson JI, Yang L, Allen TM, Luster AD, Tager AM, Dykxhoorn DM, Lieberman J.

J Clin Invest. 2011 Jun;121(6):2401-12. doi: 10.1172/JCI45876. Epub 2011 May 16.

9.

Adaptation of subtype a human immunodeficiency virus type 1 envelope to pig-tailed macaque cells.

Humes D, Overbaugh J.

J Virol. 2011 May;85(9):4409-20. doi: 10.1128/JVI.02244-10. Epub 2011 Feb 16.

10.

Novel peptides based on HIV-1 gp120 sequence with homology to chemokines inhibit HIV infection in cell culture.

Chertov O, Zhang N, Chen X, Oppenheim JJ, Lubkowski J, McGrath C, Sowder RC 2nd, Crise BJ, Malyguine A, Kutzler MA, Steele AD, Henderson EE, Rogers TJ.

PLoS One. 2011 Jan 11;6(1):e14474. doi: 10.1371/journal.pone.0014474.

11.

The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1.

Cicala C, Martinelli E, McNally JP, Goode DJ, Gopaul R, Hiatt J, Jelicic K, Kottilil S, Macleod K, O'Shea A, Patel N, Van Ryk D, Wei D, Pascuccio M, Yi L, McKinnon L, Izulla P, Kimani J, Kaul R, Fauci AS, Arthos J.

Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20877-82. doi: 10.1073/pnas.0911796106. Epub 2009 Nov 20.

12.

Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.

Du SX, Idiart RJ, Mariano EB, Chen H, Jiang P, Xu L, Ostrow KM, Wrin T, Phung P, Binley JM, Petropoulos CJ, Ballantyne JA, Whalen RG.

Virology. 2009 Dec 5;395(1):33-44. doi: 10.1016/j.virol.2009.07.042. Epub 2009 Oct 8.

13.

Prospects for antisense peptide nucleic acid (PNA) therapies for HIV.

Pandey VN, Upadhyay A, Chaubey B.

Expert Opin Biol Ther. 2009 Aug;9(8):975-89. doi: 10.1517/14712590903052877. Review.

14.

Engineering of a human vaginal Lactobacillus strain for surface expression of two-domain CD4 molecules.

Liu X, Lagenaur LA, Lee PP, Xu Q.

Appl Environ Microbiol. 2008 Aug;74(15):4626-35. doi: 10.1128/AEM.00104-08. Epub 2008 Jun 6.

15.

Monitoring early fusion dynamics of human immunodeficiency virus type 1 at single-molecule resolution.

Dobrowsky TM, Zhou Y, Sun SX, Siliciano RF, Wirtz D.

J Virol. 2008 Jul;82(14):7022-33. doi: 10.1128/JVI.00053-08. Epub 2008 May 14.

16.

The Ixodes scapularis salivary protein, salp15, prevents the association of HIV-1 gp120 and CD4.

Juncadella IJ, Garg R, Bates TC, Olivera ER, Anguita J.

Biochem Biophys Res Commun. 2008 Feb 29;367(1):41-6. Epub 2007 Dec 26.

17.

Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus.

Xie H, Ng D, Savinov SN, Dey B, Kwong PD, Wyatt R, Smith AB 3rd, Hendrickson WA.

J Med Chem. 2007 Oct 4;50(20):4898-908. Epub 2007 Sep 6.

18.

Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.

Yang QE, Stephen AG, Adelsberger JW, Roberts PE, Zhu W, Currens MJ, Feng Y, Crise BJ, Gorelick RJ, Rein AR, Fisher RJ, Shoemaker RH, Sei S.

J Virol. 2005 May;79(10):6122-33.

19.

Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein.

Xiang SH, Kwong PD, Gupta R, Rizzuto CD, Casper DJ, Wyatt R, Wang L, Hendrickson WA, Doyle ML, Sodroski J.

J Virol. 2002 Oct;76(19):9888-99.

20.

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.

Fouts T, Godfrey K, Bobb K, Montefiori D, Hanson CV, Kalyanaraman VS, DeVico A, Pal R.

Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11842-7. Epub 2002 Aug 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk